PT  - JOURNAL ARTICLE
AU  - Yanis Ramdani
AU  - Jean Marc  Galempoix
AU  - Jean François  Augusto
AU  - Eva Dekmeer
AU  - Laurent Perard
AU  - Nicole Ferreira
AU  - Adrien Bigot
AU  - Julie Magnant
AU  - Stéphanie Jobard
AU  - Elisabeth Diot
AU  - Marie Charlotte  Besse
AU  - Hélène Henrique
AU  - François Maillot
AU  - Alexandra Audemard-Verger
TI  - Immunoglobulin A Vasculitis Following COVID-19: A French Multicenter Case Series
AID  - 10.3899/jrheum.220503
DP  - 2022 Sep 01
TA  - The Journal of Rheumatology
PG  - jrheum.220503
4099  - http://www.jrheum.org/content/early/2022/10/10/jrheum.220503.short
4100  - http://www.jrheum.org/content/early/2022/10/10/jrheum.220503.full
AB  - Objective Immunoglobulin A vasculitis (IgAV) usually occurs following viral respiratory tract infection. In the context of the global coronavirus disease 2019 (COVID-19) pandemic, we describe a case series of patients who developed IgAV following SARS-CoV-2 infection. Methods This national multicenter retrospective study included patients with IgAV following SARS-CoV-2 infection from January 1, 2020, to January 1, 2022. Patients had histologically proven IgAV and reverse transcription PCR (RT-PCR)-proven SARS-CoV-2 infection. The interval between infection and vasculitis onset had to be < 4 weeks. Results We included 5 patients, 4 of whom were women with a mean age of 45 years. Four patients had paucisymptomatic infections and 1 required a 48-hour low-flow oxygen treatment. All 5 patients had purpuric skin involvement. Arthritis was observed in 2 patients, 3 had IgA glomerulonephritis, and 2 had digestive involvement. Three renal biopsies were performed and showed mesangial IgA deposits without any extracapillary proliferation. Median C-reactive protein was 180 (range 15.1-225) mg/L, median serum creatinine level was 65 (range 41-169) μmol/L, and 2 patients had a glomerular filtration rate < 60 mL/min. Four patients received first-line treatment with glucocorticoids. All patients had a favorable progression and 2 patients experienced minor skin relapses, one after COVID-19 vaccination. Conclusion This series describes the emergence of IgAV closely following COVID-19; we were not able to eliminate an incidental link between these events. Their disease outcomes were favorable. In most of our patients, the SARS-CoV-2 infection was paucisymptomatic, and we recommend RT-PCR tests to look for COVID-19 in patients without any evident triggers for IgAV.